OncoMatch/Clinical Trials/NCT07109518
uCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies
Is NCT07109518 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies uCD7 CART for acute myeloid leukemia (aml).
Treatment: uCD7 CART — The aim of this study was to evaluate the safety and efficacy of universal CD7 CART (uCD7 CART) cells in the treatment of patients with relapsed/refractory CD7-positive hematologic malignancies. In this single-arm, open-label, single-center, Phase 1 clinical trial, two cohorts were set up: (1) relapsed and refractory acute myeloid leukemia (AML) cohort; and (2) relapsed and refractory T lymphoblastic leukemia/lymphoma (T-ALL/LBL) cohort. Each cohort was planned to enroll 4-12 patients. uCD7 CART cells will be administered intravenously to explore the maximum tolerated dose (MTD) of each cohort using a 3+3 dose escalation and rapid titration design.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD7 overexpression (positive)
Cytology confirmed that the tumor cells were CD7 positive.
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: systemic chemotherapy
Exception: except for pretreatment; within 1 week
Systemic chemotherapy (except for pretreatment) within 1 week
Cannot have received: monoclonal antibody therapy
Exception: last infusion less than 5 half-lives or 4 weeks (whichever is shorter) at screening
For those who have received monoclonal antibody therapy, the last time of monoclonal antibody infusion is less than 5 half-lives or 4 weeks (whichever is shorter) at screening
Cannot have received: donor lymphocyte infusion
Exception: within 6 weeks
Received donor lymphocyte infusion (DLI) within 6 weeks
Lab requirements
Kidney function
creatine clearance >60ml/min (cockcroft and gault formula)
Liver function
serum total bilirubin ≤3 times the upper limit of normal, serum alt and ast ≤5 times the upper limit of normal range for patients without liver invasion
Cardiac function
echocardiography showing left ventricular ejection fraction (lvef) ≥50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify